CHICAGO, July 20 (Reuters) - Boston Scientific Corp on Tuesday reported a second-quarter profit that was better than expected as sales of its implanted heart defibrillators recovered from a one-month shipment halt this spring.
Second-quarter net income was $98 million, or 6 cents a share, down from $158 million, or 10 cents a share, a year ago.
Sales fell to $1.93 billion from $2.07 billion.
Analysts on average expected the Natick, Massachusetts-based medical device maker to earn 3 cents a share, according to Thomson Reuters I/B/E/S.
In post-market trading, Boston Scientific shares were up 2.1 percent from a close of $6.27 Tuesday on the New York Stock Exchange.
(Reporting by Susan Kelly, editing by Leslie Gevirtz) Keywords: BOSTONSCIENTIFIC/ (susan.kelly@thomsonreuters.com; phone 312 408 8134; Reuters Messaging: susan.kelly.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Second-quarter net income was $98 million, or 6 cents a share, down from $158 million, or 10 cents a share, a year ago.
Sales fell to $1.93 billion from $2.07 billion.
Analysts on average expected the Natick, Massachusetts-based medical device maker to earn 3 cents a share, according to Thomson Reuters I/B/E/S.
In post-market trading, Boston Scientific shares were up 2.1 percent from a close of $6.27 Tuesday on the New York Stock Exchange.
(Reporting by Susan Kelly, editing by Leslie Gevirtz) Keywords: BOSTONSCIENTIFIC/ (susan.kelly@thomsonreuters.com; phone 312 408 8134; Reuters Messaging: susan.kelly.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.